© 2008 Alexis Corporation
You are here:
Product Lines
>
Signal Transduction
> Kinases / Related Products
Diacylglycerol Kinases / Related Products
Phospho-specific Antibodies
Phosphoinositide 3-kinase [PI(3)K] / Related Products
Protein Kinase Inhibitors
Serine / Threonine Kinases / Related Products
Staurosporine / Related Products
Tyrosine Kinases / Related Products
Kinases Other Products
ALX-270-143
Revised 20-Feb-08
Tyrphostin AG 494
SYNONYMS
Tyrphostin B48
N-Phenyl-3,4-dihydroxybenzylidenecyanoacetamide
α-Cyano-(3,4-dihydroxy)-N-phenylcinnamamide
PRODUCT LINE
Signal Transduction
PRODUCT CATEGORY
Tyrphostins
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-270-143-M005
5 mg
25.00 USD
ALX-270-143-M025
25 mg
90.00 USD
Product Specification
FORMULA:
C
16
H
12
N
2
O
3
MW:
280.3
CAS NUMBER:
133550-35-3
PURITY:
≥98%
APPEARANCE:
Yellow solid.
SOLUBILITY:
Soluble in DMSO or 100% ethanol.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
-20°C
HANDLING:
Protect from light.
Product Description
Blocks CDK2 activation and causes cells to arrest at late G1 and during S phase.
Product Specific Literature References
Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases:
A. Gazit, et al.; J. Med. Chem.
34
, 1896 (1991)
Abstract
Tyrphostin AG 494 blocks Cdk2 activation:
N. Osherov & A. Levitzki; FEBS Lett.
410
, 187 (1997)
Abstract
Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase:
N. Kleinberger-Doron, et al.; Exp. Cell Res.
241
, 340 (1998)
Abstract
Further Categories Containing This Product:
EGFR Kinase Inhibitors
•
Tyrosine Kinase Inhibitors
•
CDK & Cyclin Inhibitors
•
Cell Cycle Blockers & Inhibitors / Related Products
ALX-270-168
Revised 18-May-06
Tyrphostin AG 490
SYNONYMS
Tyrphostin B42
N-Benzyl-3,4-dihydroxy-benzylidenecyanoacetamide
α-Cyano-(3,4-dihydroxy)-]N-benzylcinnamamide
PRODUCT LINE
Signal Transduction
PRODUCT CATEGORY
Tyrphostins
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-270-168-M005
5 mg
45.00 USD
ALX-270-168-M025
25 mg
190.00 USD
Product Specification
FORMULA:
C
17
H
14
N
2
O
3
MW:
294.3
CAS NUMBER:
133550-30-8
PURITY:
≥98%
APPEARANCE:
Yellow solid.
SOLUBILITY:
Soluble in DMSO and acetone; slightly soluble in 100% ethanol.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
-20°C
HANDLING:
Protect from light.
Product Description
Selectively inhibits CDK2 activation leading to a potent cell cycle arrest at late G1 and S phase. Cell permeable inhibitor of JAK-2 tyrosine kinase. Does not significantly inhibit other kinases, such as Lck, Lyn, Btk, Syk or Src. Blocks IL-7 induced JAK kinase activity in T cells (JAK-1, JAK-3) and the consequent phosphorylation of PI-3 kinase. Valuable tool for studying the cellular role of JAK kinases in signal transduction.
Product Specific Literature References
Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors:
A. Gazit, et al.; J. Med. Chem.
32
, 2344 (1989)
Abstract
Tyrosine phosphorylation is an obligatory event in IL-2 secretion [published erratum appears in J Immunol 1991 May 1;146(9):3260]:
A. Levitzki; Biochem. Pharmacol.
40
, 913 (1990)
Abstract
Activation of phosphatidylinositol-3 kinase by ligation of the interleukin-7 receptor is dependent on protein tyrosine kinase activity:
H. Dadi, et al.; Blood
84
, 1579 (1994)
Abstract
;
Full Text
JAK3 protein tyrosine kinase mediates interleukin-7-induced activation of phosphatidylinositol-3’ kinase
:
N. Sharfe, et al.; Blood
86
, 2077 (1995)
Abstract
;
Full Text
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor:
N. Meydan, et al.; Nature
379
, 645 (1996)
Abstract
Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells:
R.A. Kirken, et al.; J. Leukoc. Biol.
65
, 891 (1999)
Abstract
JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response:
L.H. Wang, et al.; J. Immunol.
162
, 3897 (1999)
Abstract
JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells:
J. De Vos, et al.; Br. J. Haematol.
109
, 823 (2000)
Abstract
Further Categories Containing This Product:
Janus Kinases [JAKs] / Related Products
•
Tyrosine Kinase Inhibitors
•
CDK & Cyclin Inhibitors
•
Cell Cycle Blockers & Inhibitors / Related Products
ALX-270-246
Revised 28-Sep-07
Purvalanol A
SYNONYMS
6-[(3-Chloro)anilino]-2(1R)-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine
PRODUCT LINE
Cell Cycle
PRODUCT CATEGORY
CDK & Cyclin Inhibitors
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-270-246-M001
1 mg
55.00 USD
ALX-270-246-M005
5 mg
220.00 USD
Product Specification
FORMULA:
C
19
H
25
N
6
OCl
MW:
388.9
PURITY:
≥99%
APPEARANCE:
Off-white to yellow powder.
SOLUBILITY:
Soluble in DMSO, methanol or dichloromethane.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
-20°C
HANDLING:
Keep cool and dry. Keep under inert gas.
Product Description
Inhibitor of human CDK1 (IC
50
=4nM), CDK2/cyclin A (IC
50
=70nM), Cdc2/cyclin B, CDK2/cyclin E (IC
50
=35nM), CDK4/cyclin D1 (IC
50
=850nM) as well as CDK5/p35 (IC50=75nM). More membrane permeable than purvalanol B.
Product Specific Literature References
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors:
N.S. Gray, et al.; Science
281
, 533 (1998)
Abstract
Up-regulation of cdc2 protein during paclitaxel-induced apoptosis:
P. Chadebech, et al.; Int. J. Cancer
87
, 779 (2000)
Abstract
Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons:
E.A. Monaco, 3rd, et al.; Biochem. Pharmacol.
67
, 1947 (2004)
Abstract
ALX-270-248
Revised 17-Jul-07
Compound 52
SYNONYMS
2-(2-Hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine
PRODUCT LINE
Cell Cycle
PRODUCT CATEGORY
CDK & Cyclin Inhibitors
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-270-248-M001
1 mg
55.00 USD
Product Specification
FORMULA:
C
16
H
19
ClN
6
O
MW:
346.8
PURITY:
≥99%
APPEARANCE:
Off-white solid.
SOLUBILITY:
Soluble in DMSO or methanol.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
-20°C
Product Description
Potent, cell permeable and selective inhibitor of CDK1 (IC
50
=340nM) the cell cycle-regulating kinase Cdc28p (IC
50
=7µM) and the related Pho85p kinase (IC
50
=2µM).
Product Specific Literature References
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors:
N.S. Gray, et al.; Science
281
, 533 (1998)
Abstract
ALX-270-249
Revised 11-Sep-08
Aminopurvalanol A
SYNONYMS
(2
R
)-2-((6-((3-Amino-5-chlorophenyl)amino)-9-(1-methylethyl)-
9
H
-purin-2-yl)amino)-3-methyl-1-butanol
NG-97
PRODUCT LINE
Cell Cycle
PRODUCT CATEGORY
CDK & Cyclin Inhibitors
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-270-249-M001
1 mg
45.00 USD
ALX-270-249-M005
5 mg
135.00 USD
Product Specification
FORMULA:
C
19
H
26
N
7
OCl
MW:
403.9
CAS NUMBER:
220792-57-4
PURITY:
≥97% (
1
H-NMR)
APPEARANCE:
White to brownish solid.
SOLUBILITY:
Soluble in DMSO or methanol.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
+4°C
HANDLING:
Packaged under inert gas. Protect from light.
HAZARD:
IRRITANT.
Product Description
Cell permeable, reversible and competitive inhibitor of CDK1/cyclin B (IC
50
=33nM), CDK2/cyclin A (IC
50
=33nM), CDK2/cyclin E (IC
50
=28nM) and CDK5/p35 (IC
50
=20nM).
Product Specific Literature References
Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors:
Y.T. Chang, et al.; Chem. Biol.
6
, 361 (1999)
Abstract
A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts:
G.R. Rosania, et al.; PNAS
96
, 4797 (1999)
Abstract
;
Full Text
M-phase regulation of the recruitment of mRNAs onto polysomes using the CDK1/cyclin B inhibitor aminopurvalanol:
M. Le Breton, et al.; BBRC
306
, 880 (2003)
Abstract
ALX-270-271
Revised 17-Jul-07
Indirubin-3'-monoxime
PRODUCT LINE
Cell Cycle
PRODUCT CATEGORY
CDK & Cyclin Inhibitors
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-270-271-M001
1 mg
50.00 USD
ALX-270-271-M005
5 mg
190.00 USD
Product Specification
FORMULA:
C
16
H
11
N
3
O
2
MW:
277.3
PURITY:
≥98% (
1
H-NMR)
APPEARANCE:
Dark red powder.
SOLUBILITY:
Soluble in DMSO.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
-20°C
Product Description
Selective and strong inhibitor of cyclin-dependent kinases (CDKs). Inhibits CDK1/cyclin B (IC
50
=180nM), CDK2/cyclin A (IC
50
~500nM), CDK2/cyclin E (IC
50
=250nM), CDK4/cyclin D1 (IC
50
=3.3µM) and CDK5/p35 (IC
50
=100nM). Inhibits the proliferation of a large range of cells, mainly through arresting the cells in the G2/M phase of the cell cycle. Powerful inhibitor of GSK-3β (IC
50
~100nM) and tau phosphorylation
in vitro
and
in vivo
at Alzheimer’s disease-specific sites.
Product Specific Literature References
Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases:
R. Hoessel, et al.; Nature Cell Biol.
1
, 60 (1999)
Abstract
;
Full Text
Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest
:
E. Damiens, et al.; Oncogene
20
, 3786 (2001)
Abstract
;
Full Text
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?:
S. Leclerc, et al.; J. Biol. Chem.
276
, 251 (2001)
Abstract
;
Full Text
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells
:
D. Marko, et al.; Br. J. Cancer
84
, 283 (2001)
Abstract
;
Full Text
Related Products
ALX-270-424
5-Iodo-indirubin-3'-monoxime
ALX-270-296
Indirubin-5-sulfonic acid . sodium salt
ALX-430-149
7BIO
ALX-270-361
Indirubin
ALX-430-156
6BIO
ALX-430-157
Me-7BIO
Further Categories Containing This Product:
Tau / Related Products
•
Cell Cycle Blockers & Inhibitors / Related Products
•
GSK-3 Inhibitors
ALX-270-274
Revised 13-Sep-07
Kenpaullone
SYNONYMS
9-Bromo-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5
H
)-one
PRODUCT LINE
Cell Cycle
PRODUCT CATEGORY
CDK & Cyclin Inhibitors
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-270-274-M001
1 mg
60.00 USD
ALX-270-274-M005
5 mg
270.00 USD
Product Specification
FORMULA:
C
16
H
11
BrN
2
O
MW:
327.2
CAS NUMBER:
142273-20-9
PURITY:
≥95%
APPEARANCE:
Brown powder.
SOLUBILITY:
Soluble in DMSO; insoluble in water or ethanol.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
+4°C
Product Description
Potent inhibitor of CDK1/cyclin B (IC
50
=400nM). Also inhibits CDK2/cyclin A (IC
50
=680nM) , CDK5 (IC
50
=850nM) and with much less effect other kinases.
Licensed from NCI.
Product Specific Literature References
ATP-site directed inhibitors of cyclin-dependent kinases
:
N. Gray, et al.; Curr. Med. Chem.
6
, 859 (1999)
Abstract
Fused azepinones with antitumor activity:
C. Kunick; Curr. Pharm. Des.
5
, 181 (1999), (Review)
Abstract
Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity:
C. Schultz, et al.; J. Med. Chem.
42
, 2909 (1999)
Abstract
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases:
D.W. Zaharevitz, et al.; Cancer Res.
59
, 2566 (1999)
Abstract
Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition
:
R. Gussio; Anticancer Drug Des.
15
, 53 (2000)
Abstract
2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity
:
C. Kunick, et al.; Bioorg. Med. Chem. Lett.
10
, 567 (2000)
Abstract
Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25
:
M. Leost, et al.; Eur. J. Biochem.
267
, 5983 (2000)
Abstract
Inhibition of CDKs as a therapeutic modality
:
E.A. Sausville, et al.; Ann. NY Acad. Sci.
910
, 207 (2000)
Abstract
ALX-270-275
Revised 11-Sep-08
Alsterpaullone
SYNONYMS
9-Nitro-7,12-dihydroindolo-[3,2-
d
][1]benzazepin-6(5
H
)-one
PRODUCT LINE
Cell Cycle
PRODUCT CATEGORY
CDK & Cyclin Inhibitors
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-270-275-M001
1 mg
60.00 USD
ALX-270-275-M005
5 mg
270.00 USD
Product Specification
FORMULA:
C
16
H
11
N
3
O
3
MW:
293.3
CAS NUMBER:
237430-03-4
PURITY:
≥95% (HPLC)
APPEARANCE:
Yellow to brown powder.
SOLUBILITY:
Soluble in DMSO; insoluble in water or 100% ethanol.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
+4°C
IDENTITY:
Identity determined by IR,
1
H-NMR and
13
C-NMR.
Product Description
Potent inhibitor of CDK1/cyclin B (IC
50
=35nM). Potent and selective inhibitor of CDK2/cyclin A, CDK2/cyclin E (IC
50
=200nM), CDK5/p25 (IC
50
=40nM), CDK5/p35 (IC
50
=40nM) and GSK-3β . Induces apoptosis by activation of caspase-8 and caspase-9 followed by disruption of the mitochondrial potential.
Licensed from NCI.
Product Specific Literature References
ATP-site directed inhibitors of cyclin-dependent kinases
:
N. Gray, et al.; Curr. Med. Chem.
6
, 859 (1999)
Abstract
Fused azepinones with antitumor activity:
C. Kunick; Curr. Pharm. Des.
5
, 181 (1999), (Review)
Abstract
Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity:
C. Schultz, et al.; J. Med. Chem.
42
, 2909 (1999)
Abstract
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases
:
D.W. Zaharevitz, et al.; Cancer Res.
59
, 2566 (1999)
Abstract
2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity
:
C. Kunick, et al.; Bioorg. Med. Chem. Lett.
10
, 567 (2000)
Abstract
Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25
:
M. Leost, et al.; Eur. J. Biochem.
267
, 5983 (2000)
Abstract
Inhibition of CDKs as a therapeutic modality
:
E.A. Sausville, et al.; Ann. NY Acad. Sci.
910
, 207 (2000)
Abstract
A novel, extraneuronal role for cyclin-dependent protein kinase 5 (CDK5): modulation of cAMP-induced apoptosis in rat leukemia cells
:
T. Sandal, et al.; J. Biol. Chem.
277
, 20783 (2002)
Abstract
;
Full Text
Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor
:
M. Knockaert, et al.; J. Biol. Chem.
277
, 25493 (2002)
Abstract
;
Full Text
Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential
:
T. Lahusen, et al.; Mol Carcinog
36
, 183 (2003)
Abstract
The specificities of protein kinase inhibitors: an update
:
J. Bain, et al.; Biochem. J.
371
, 199 (2003)
Abstract
Further Categories Containing This Product:
Apoptosis Inducers & Inhibitors Other Products
•
GSK-3 Inhibitors
ALX-270-282
Revised 18-Jul-07
9-Cyanopaullone
SYNONYMS
9-Cyano-7,12-dihydroindolo-[3,2-
d
][1]benzazepin-6[5
H
]-one
PRODUCT LINE
Cell Cycle
PRODUCT CATEGORY
CDK & Cyclin Inhibitors
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-270-282-M001
1 mg
70.00 USD
ALX-270-282-M005
5 mg
280.00 USD
Product Specification
FORMULA:
C
17
H
11
N
3
O
MW:
273.3
PURITY:
≥95%
SOLUBILITY:
Soluble in DMSO; insoluble in water or ethanol.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
+4°C
Product Description
Very potent inhibitor of CDK1/cyclin B (IC
50
=25nM). Also inhibits CDK5/p25 (IC
50
=44nM ) and GSK-3β (IC
50
=10nM).
Licensed
from NCI.
Product Specific Literature References
ATP-site directed inhibitors of cyclin-dependent kinases
:
N. Gray, et al.; Curr. Med. Chem.
6
, 859 (1999)
Abstract
Fused azepinones with antitumor activity
:
C. Kunick; Curr. Pharm. Des.
5
, 181 (1999)
Abstract
Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity
:
C. Schultz, et al.; J. Med. Chem.
42
, 2609 (1999)
Abstract
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases
:
D.W. Zaharevitz, et al.; Cancer Res.
59
, 2566 (1999)
Abstract
Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition
:
R. Gussio, et al.; Anticancer Drug Des.
15
, 53 (2000)
Abstract
2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity
:
C. Kunick, et al.; Bioorg. Med. Chem. Lett.
10
, 567 (2000)
Abstract
Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25
:
M. Leost, et al.; Eur. J. Biochem.
267
, 5983 (2000)
Abstract
Inhibition of CDKs as a therapeutic modality
:
E.A. Sausville, et al.; Ann. NY Acad. Sci.
910
, 207 (2000)
Abstract
ALX-270-296
Revised 15-Aug-08
Indirubin-5-sulfonic acid . sodium salt
SYNONYMS
E226
Indirubin-5-sulphonate . Na
PRODUCT LINE
Cell Cycle
PRODUCT CATEGORY
CDK & Cyclin Inhibitors
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-270-296-M001
1 mg
75.00 USD
ALX-270-296-M005
5 mg
300.00 USD
Product Specification
FORMULA:
C
16
H
9
N
2
O
5
S . Na
MW:
341.3 . 23.0
PURITY:
≥95% (
1
H-NMR)
APPEARANCE:
Black powder.
SOLUBILITY:
Soluble in DMSO or water.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
-20°C
Product Description
Inhibitor of cyclin-dependent kinases (CDKs), with selectivity for CDK1/cyclin B (IC
50
=55nM), CDK2/cyclin A (IC
50
=35nM), CDK2/cyclin E (IC
50
=150nM), CDK4/cyclin D1 (IC
50
=300nM), CDK5/p35 (IC
50
=65nM) and GSK-3β (IC
50
=280nM).
Product Specific Literature References
Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases:
R. Hoessel, et al.; Nat. Cell. Biol.
1
, 60 (1999)
Inhibitor binding to active and inactive cdk2. the crystal structure of cdk2-cyclin a/indirubin-5-sulphonate:
T.G. Davies, et al.; Structure (Camb)
9
, 389 (2001)
Abstract
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells:
D. Marko, et al.; Br. J. Cancer
84
, 283 (2001)
Abstract
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?:
S. Leclerc, et al.; J. Biol. Chem.
276
, 251 (2001)
Abstract
;
Full Text
Related Products
ALX-430-157
Me-7BIO
ALX-430-156
6BIO
ALX-270-271
Indirubin-3'-monoxime
ALX-430-149
7BIO
ALX-270-424
5-Iodo-indirubin-3'-monoxime
ALX-270-361
Indirubin
Further Categories Containing This Product:
GSK-3 Inhibitors
ALX-270-300
Revised 05-Apr-08
Fascaplysin
PRODUCT LINE
Natural Products / Antibiotics
PRODUCT CATEGORY
Natural Products for Cell Cycle Research
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-270-300-M001
1 mg
60.00 USD
ALX-270-300-M005
5 mg
240.00 USD
